Mind Cure Health Is Shutting Down All Operations, Citing Lack Of Funds To Move Forward
Mind Cure Health Is Shutting Down All Operations, Citing Lack Of Funds To Move Forward
Mind Cure Health Inc. (CSE:MCUR) (OTCQX:MCURF) (FRA: 6MH), a mental health and wellness company working in the psychedelics sector, announced that a special committee its board of directors concluded a review process and has determined that the capital required to continue the Company's business plan is unlikely to be found under the current and foreseeable market conditions.
心靈治療健康公司。(CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH), 一家在迷幻藥領域工作的心理健康和健康公司, 宣布，一個特別委員會的董事會總結了一個特別委員會 審查過程，並確定在當前和可預見的市場狀況下，不太可能找到繼續公司業務計劃所需的資本。
Shutting Down
關閉
As such, the Board decided to immediately eliminate all expenditures outside those required to preserve the value of the Company's assets and will immediately cut all of its C-suite executives and employees, except for its CFO, vice president of engineering and certain administrative staff required to wind-down the its operations.
因此，董事會決定 立即消除保持公司資產價值所需的支出以外的所有支出並將立即削減其所有 C 級管理人員和員工，除了其首席財務官，工程副總裁和某些行政人員需要減少其運營。
"Though we continue the Strategic Review Process, we have identified no available strategic alternatives that would require further development and execution of MINDCURE's existing business plan," said the chair of MINDCURE's Special Committee, Jason Pamer.
MINDCURE 特別委員會主席說：「儘管我們繼續進行戰略審查流程，但我們確定沒有任何可用的戰略替代方案，這將需要進一步發展和執行 MINDCURE 現有的業務計劃，傑森·帕米爾。
The Company will also stop all non-committed expenditures related to the development and marketing work of its iSTRYM product, R&D related to its synthetic ibogaine program and R&D related to its Desire Project.
該公司也將停止 與其 iStrym 產品的開發和營銷工作有關的所有非承諾支出，與其合成 ibogaine 計劃和與其慾望項目相關的研發相關的研發。
"While we truly appreciate the impact of these changes on our team and our suppliers, our Strategic Review Process has led us to believe that the actions announced in this news release are necessary to preserve cash position and maintain value of the Company's other assets while the Company continues to seek a strategic transaction," said Philip Tapley, chair of MINDCURE's board of directors and interim CEO.
「儘管我們非常感謝這些變化對我們團隊和供應商的影響，但我們的策略審查流程使我們相信，在公司繼續尋求策略性交易的同時，本新聞稿中宣布的行動對於保持公司其他資產的現金狀況並維持公司其他資產的價值是必要的。」 菲利普·塔普利,智治醫療董事會主席兼臨時行政總裁。
Other than what was described in a company press release, Mind Cure has not announced any decisions related to strategic alternatives or expressed assurances regarding the evaluation of strategic alternatives.
除了公司新聞稿中描述的內容, Mind Cure 尚未宣布與戰略替代方案有關的任何決定或表示保證有關戰略替代品的評估.
"The Company does not intend to comment further unless and until further disclosure is appropriate or necessary," according the release.
該新聞稿稱：「除非及直至進一步披露適當或必要，否則公司不打算進一步評論。」
Mind Cure's stock stopped trading when the news was announced but did resume after a few hours and then fell by 38%.
Mind Cure 的股票在消息宣布時停止交易，但幾個小時後確實恢復了，然後下跌了 38％。
譯文內容由第三人軟體翻譯。